An observational study in Leishmaniasis, Visceral, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 5 sites in Italy. Open to participants aged 6 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-01-27.
Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational
According to reports in the literature, from 2012 to date, there has been an increase in the number of diagnosed cases of autochthonous visceral Leishmania in the Province of Bologna.
In this context, it was decided to carry out a retrospective prospective observational study, which is essential to describe the epidemiology of LV in order to outline the scientific and rational bases necessary for the drafting of guidelines to standardise the diagnostic and therapeutic approach to this disease, in order to reduce the diagnostic delay and improve therapeutic results.
therapeutic outcome. In addition, epidemiological data will make it possible to identify possible new strategies to control the disease, which are essential for reducing its transmission.
The term leishmaniasis refers to a heterogeneous group of anthropo-zoonoses caused by protozoa obligate intracellular protozoa, parasites of humans and various wild and domestic animals, belonging to the genus Leishmania. Despite being the cause of recurrent epidemic outbreaks with high rates of morbidity and mortality rates in certain geographical areas, the World Health Organisation (WHO) includes them among the Neglected Tropical Diseases. About 350 million people live in areas at risk for leishmaniasis with an estimated global prevalence of 12 million. The annual global incidence is estimated to be between 0.2 and 0.4 million cases for Visceral Leishmaniasis (LV) and between 0.7 and 1.2 million cases for Cutaneous Leishmaniasis Cutaneous. Leishmaniases are endemic infections in tropical, subtropical and temperate zones of all continents except Australia and Antarctica. More than 90% of LV cases are diagnosed in six countries: Bangladesh, Brazil, Ethiopia, India, South Sudan and Sudan, while the majority of LC cases are diagnosed in Afghanistan, Algeria, Brazil, Colombia, Iran, Pakistan, Peru, Saudi Arabia and Syria.
Leishmaniasis is also endemic in the Mediterranean Basin, including Italy, and in this area about 5% of global cases are found there, with a clear prevalence of visceral forms.
The incubation period varies from 4 to 10 months, but cases have been described in which incubation lasted for several years.
The onset is mostly gradual and insidious and the most characteristic clinical manifestations are asthenia fever (often initially framed as FUO), night sweats, anorexia and weight loss, splenomegaly, hepatomegaly and lymphadenomegaly. From a laboratory point of view, characteristic are anaemia, leucopenia and thrombocytopenia, more or less associated with each other, up to full-blown pancytopenia.
Dysprotidemia with hypergammaglobulinemia and hypoalbuminemia is typical. If not adequately treated, visceral leishmaniasis evolves towards a condition of cachexia and profound general decay and may prove fatal. A rare and serious complication of LV is the haemophagocytic syndrome. According to the 2010 WHO Leishmaniasis Control Report, a confirmed case of LV is defined as the association between typical clinical signs and symptoms (fever, splenomegaly, weight loss, etc.) and positivity of a parasitological examination (microscopy, RT-PCR or culture) in the presence or absence of positivity of serological investigations.
The methods available for the diagnosis of LV include:
Quantitative RT-PCR on peripheral blood may be useful in patients immunocompromised patients for monitoring parasitukaemia during therapy.
Direct microscopic examination on bone marrow blood smear: sensitivity is variable (25-85%) and lower than the sensitivity of molecular methods.
According to reports in the literature, from 2012 to date, there has been an increase in the number of diagnosed cases of autochthonous visceral Leishmania in the Province of Bologna.
In this context, it was decided to carry out a retrospective prospective observational study, which is essential to describe the epidemiology of LV in order to outline the scientific and rational bases necessary for the drafting of guidelines to standardise the diagnostic and therapeutic approach to this disease, in order to reduce the diagnostic delay and improve therapeutic results.
therapeutic outcome. In addition, epidemiological data will make it possible to identify possible new strategies to control the disease, which are essential for reducing its transmission.
68 studies on the registry are indexed under Leishmaniasis, Visceral; 7 are open to participants now.
This study's planned enrollment of 300 is below the median of 400 across 19 observational studies indexed under Leishmaniasis, Visceral.
Browse Leishmaniasis, Visceral studies →IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 511 studies on the registry; 287 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Any patient with a diagnosis of established Visceral Leishmaniasis but also patients with a diagnosis of prior Visceral Leishmaniasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epidemiology of Visceral Leishmaniasis (VL) cases in Emilia-Romagna
In-depth description of the epidemiology of autochthonous visceral Leishmaniasis in the Emilia-Romagna region, focusing on the increase in diagnosed cases since 2012. The study will provide critical data for identifying trends in incidence, affected populations, and geographical hotspots, essential for guiding public health interventions. Measure: Number of diagnosed cases per year across participating centers. Unit of measure: Number of cases (n). Collection method: Review of medical records and epidemiological registries.
Time frame: March 2020 - February 2025
Socio-demographic and clinical characteristics of patients diagnosed with VL
Detailed analysis of the clinical features and presentations of diagnosed LV cases, including common symptoms such as fever, weight loss, splenomegaly, and laboratory findings like anemia and pancytopenia. This analysis will help establish a clearer clinical profile for early diagnosis and treatment strategies. Measure: Age, gender, comorbidities, geographic area of residence, known exposure mode. Unit of measure: Mean ± standard deviation (continuous variables), percentages (categorical variables). Collection method: clinical data collection.
Time frame: March 2020 - February 2025
Diagnostic accuracy of methods used for VL identification
Evaluation of the diagnostic accuracy of available methods (serological tests, RT-PCR, direct microscopy, and culture) in identifying LV cases, particularly in immunocompromised patients and those with atypical presentations. The study will assess the effectiveness of these tests in different clinical scenarios, including their sensitivity and specificity. Measure: Sensitivity, specificity, positive and negative predictive values of diagnostic tests (EIA, IFAT, RT-PCR, rK39 ICT, direct microscopy). Unit of measure: Percentage (%). Collection method: Comparison with the diagnostic gold standard (bone marrow biopsy with parasite identification).
Time frame: March 2020 - February 2025
Monitoring of therapy tolerability
Ongoing assessment of the safety and tolerability of therapeutic interventions used to treat LV, with a focus on identifying potential adverse effects or complications arising from current treatment regimens. This includes monitoring for any therapy-related side effects and evaluating the suitability of treatment options in different patient populations. Measure: Number of participants with adverse events (evaluated according to CTCAE v4.0 criteria). Unit of measure: Number of adverse events (n), percentage (%). Collection method: Adverse event reporting forms and clinical reports.
Time frame: March 2020 - February 2025
Evaluation of therapeutic outcomes of treated cases.
Comprehensive assessment of the therapeutic outcomes in patients treated for LV, measuring the effectiveness of current treatment protocols in terms of clinical improvement, survival rates, and relapse prevention. This will also involve tracking long-term patient recovery and any subsequent need for retreatment. Measure: Complete cure rate, recurrence rate at 6 and 12 months, disease-related mortality. Unit of measure: Percentage (%), time to recurrence in days (d). Collection method: Clinical and laboratory follow-up.
Time frame: March 2020 - February 2025
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2020 (actual). Primary completion is estimated for May 2025, 61 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Azienda Ospedaliero-Universitaria di Bologna →